Blue Trust Inc. Grows Holdings in McKesson Corporation $MCK

Blue Trust Inc. raised its position in shares of McKesson Corporation (NYSE:MCK) by 13.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,932 shares of the company’s stock after purchasing an additional 719 shares during the quarter. Blue Trust Inc.’s holdings in McKesson were worth $5,133,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Cullen Investment Group LTD. increased its holdings in shares of McKesson by 550.4% in the fourth quarter. Cullen Investment Group LTD. now owns 4,670 shares of the company’s stock worth $3,811,000 after purchasing an additional 3,952 shares during the last quarter. Pensionfund Sabic purchased a new stake in shares of McKesson in the fourth quarter worth about $1,887,000. Achmea Investment Management B.V. boosted its stake in McKesson by 7.5% during the third quarter. Achmea Investment Management B.V. now owns 61,287 shares of the company’s stock valued at $47,347,000 after buying an additional 4,260 shares during the last quarter. Investment Research Partners LLC bought a new position in McKesson during the third quarter valued at approximately $1,303,000. Finally, Horizon Investments LLC grew its holdings in McKesson by 125.4% during the 4th quarter. Horizon Investments LLC now owns 8,679 shares of the company’s stock valued at $7,119,000 after buying an additional 4,828 shares in the last quarter. 85.07% of the stock is currently owned by institutional investors.

Key McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson announced a $179 million, state-of-the-art pharmaceutical distribution center in Moore, Oklahoma, a sign of continued investment in its healthcare logistics network and capacity expansion. McKesson Selects Moore, Oklahoma for $179 Million State-of-the-Art Pharmaceutical Distribution Center
• Positive Sentiment: Related reports say the new Moore facility will be a 330,000-square-foot distribution hub and could create 200+ jobs, reinforcing McKesson’s role as a key healthcare supply-chain operator. McKesson picks Moore for 330,000-square-foot distribution hub, 200+ jobs expected
• Positive Sentiment: McKesson also announced its first-quarter fiscal 2027 earnings release date for August 5, which gives investors a clear near-term catalyst to watch. McKesson Corporation Announces First Quarter Fiscal 2027 Earnings Release Date
• Positive Sentiment: The company’s annual ideaShare 2026 event highlighted momentum with independent pharmacies, which may support customer relationships and future distribution demand. McKesson ideaShare 2026 Fuels Momentum for Independent Pharmacies
• Neutral Sentiment: Zacks noted that MCK is a trending stock among users, reflecting elevated investor interest rather than a fundamental change in outlook. McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: A separate portfolio update from TCW mentioned McKesson, but it does not appear to be a company-specific catalyst. TCW Concentrated Large Cap Growth Fund Q1 2026 Portfolio Activity

McKesson Trading Up 0.6%

McKesson stock opened at $768.14 on Thursday. The firm has a 50-day moving average price of $781.47 and a 200-day moving average price of $841.13. The firm has a market capitalization of $89.93 billion, a PE ratio of 19.97, a price-to-earnings-growth ratio of 1.26 and a beta of 0.31. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Thursday, May 7th. The company reported $11.69 EPS for the quarter, beating the consensus estimate of $11.56 by $0.13. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. The company had revenue of $96.30 billion for the quarter, compared to the consensus estimate of $101.35 billion. During the same period in the prior year, the firm posted $10.12 EPS. The firm’s revenue was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. As a group, sell-side analysts predict that McKesson Corporation will post 44.28 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio is currently 8.53%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Barclays decreased their price objective on McKesson from $1,050.00 to $925.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. Leerink Partners reissued an “outperform” rating and issued a $1,085.00 target price on shares of McKesson in a report on Thursday, March 5th. UBS Group boosted their price target on shares of McKesson from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $875.00 price target on shares of McKesson in a research note on Friday, May 8th. Finally, Bank of America lowered their price objective on shares of McKesson from $1,040.00 to $1,000.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $960.53.

Insiders Place Their Bets

In other news, CAO Napoleon B. Rutledge, Jr. sold 133 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $764.00, for a total value of $101,612.00. Following the sale, the chief accounting officer directly owned 632 shares in the company, valued at approximately $482,848. This represents a 17.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Thomas L. Rodgers sold 699 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $735.27, for a total value of $513,953.73. Following the sale, the executive vice president directly owned 2,268 shares of the company’s stock, valued at $1,667,592.36. This represents a 23.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 20,285 shares of company stock valued at $15,546,137. Corporate insiders own 0.06% of the company’s stock.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.